Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer

Prostate Cancer Metastatic Clinical Trial

Official title:

Randomized, Double-blind, Placebo Controlled, Dose Finding Phase 2 Study Comparing Oral Daily Dosing of VERU-944 to Ameliorate the Vasomotor Symptoms Resulting From ADT in Men With Advanced Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03646162
• Other study ID #: V72203
• Status: Completed
• Phase: Phase 2
• Start date: September 14, 2018
• Est. completion date: October 15, 2020

Study information

• Verified date: December 2021
• Source: Veru Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Randomized, double-blind, placebo controlled, dose finding Phase 2 study comparing oral daily dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the vasomotor symptoms resulting from androgen deprivation therapy in men with advanced prostate cancer

Description:

This study is a multicenter, randomized, double-blind, placebo controlled, dose finding study of VERU-944 to treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT. The study will have four arms with 30 subjects per arm. The subjects participating in the study will have advanced prostate cancer and will be undergoing androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone (LHRH) therapy (agonist or antagonist) for at least the three months prior to randomization and be experiencing regular moderate to severe hot flashes while on ADT. Subjects will all continue to receive ADT and will be randomized to receive, for the first four days, a loading dose followed by daily doses of placebo or VERU-944 (10 mg, 50 mg or 100 mg) orally for a total period of 12 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 93
• Est. completion date: October 15, 2020
• Est. primary completion date: April 30, 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. Be over 18 years of age;

2. Be able to communicate effectively with the study personnel;

3. Have histologically confirmed prostate cancer;

4. Have been treated with an LHRH agonist or LHRH antagonist for at least the 3 months prior to randomization;

5. Be continued on an LHRH agonist or LHRH antagonist throughout this study;

6. Have experienced hot flashes for at least one month prior to study entry;

7. Have moderate or severe vasomotor symptoms (hot flashes) (defined as a minimum of 4 moderate to severe hot flashes per day or 12 per week at baseline);

8. ECOG performance status of 0 to 2

9. Be willing to uses electronic data capture for the relevant medical events

• Must be at least 80% compliant during the screening period

10. Subjects must agree to use acceptable methods of contraception:

• If their female partners are pregnant or lactating, acceptable methods of contraception from the time of the first administration of study medication until 6 months following administration of the last dose of study medication must be used. Acceptable methods are: Condom used with spermicidal foam/gel/film/cream/suppository. If the subject has undergone surgical sterilization (vasectomy with documentation of azospermia), a condom with spermicidal foam/gel/film/cream/suppository should be used.
• If the male subject's partner could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 6 months following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/film/cream/suppository [i.e., barrier method of contraception], surgical sterilization (vasectomy with documentation of azospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}, the female partner uses oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method (condom used with spermicidal foam/gel/film/cream/suppository).
• If the female partner has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam/gel/film/cream/suppository) should also be used.
• If the female partner has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with spermicidal foam/gel/film/cream/suppository) should also be used.

11. Subject is willing to comply with the requirements of the protocol through the end of the study. Exclusion Criteria

1. Have a serum total testosterone concentration > 50 ng/dL at screening;

2. Known hypersensitivity or allergy to estrogen or estrogen like drugs;

3. Any disease or condition (medical or surgical) which might compromise the hematologic, cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk;

4. Subjects with a personal history of abnormal blood clotting or thrombotic disease, including venous or arterial thrombotic events such as a history of stroke, deep vein thrombosis (DVT), and/or pulmonary embolus (PE);

5. Any subjects, as determined by a central laboratory, that have a:

• Factor V Leiden gene mutation
• Prothrombin gene mutation

6. Uncontrolled symptomatic congestive heart failure (NYHA Class III - IV), unstable angina pectoris, cardiac arrhythmia, or uncontrolled atrial fibrillation;

7. History of MI

8. The presence of consistently abnormal laboratory values which are considered clinically significant. In addition, any subject with liver enzymes (ALT or AST) above 2 times the upper limit of normal, total bilirubin above 2 times the upper limit of normal, or serum creatinine above 1.5 times the upper limit of normal will NOT be admitted to the study;

9. Received an investigational drug within a period of 90 days prior to enrollment in the study;

10. Received the study medication (VERU-944) previously;

11. Have previously taken within 6 months prior to screening or are currently taking diethylstilbestrol, other estrogens;

12. Currently taking gabapentin, estrogen, diethylstilbestrol, medroxyprogesterone acetate, clomiphene, selective serotonin reuptake inhibitors (SSRIs), other treatments for hot flashes

13. Recent hospitalization for more than 24 hours (within 30 days of screening);

14. Recent surgery (within 30 days of screening);

15. Have been previously diagnosed or treated for active cancer (other than prostate cancer or non-melanoma skin cancer) within the previous five years;

16. Have a BMI >40.

Related Conditions & MeSH terms

• Prostate Cancer Metastatic
• Prostatic Neoplasms

Intervention

Drug:
• Veru-944
Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Urologic Consultants	Bala-Cynwyd	Pennsylvania
United States	Coastal Urology	Brick	New Jersey
United States	North Idaho Urology	Coeur d'Alene	Idaho
United States	Mary Crowley Cancer Research	Dallas	Texas
United States	Urology Clinics of North Texas	Dallas	Texas
United States	The Urology Center of Colorado	Denver	Colorado
United States	Universal Axon Clinical Research	Doral	Florida
United States	Premier Urology Group	Edison	New Jersey
United States	Advance Urology	Elmont	New York
United States	AccuMed Research	Garden City	New York
United States	Gen1 Research	Glendale	Arizona
United States	Foothills Urology	Golden	Colorado
United States	Houston Urology Partners	Houston	Texas
United States	First Urology	Jeffersonville	Indiana
United States	Tower Urology	Los Angeles	California
United States	Medical Research Center	Miami	Florida
United States	Clinical Research Solutions	Middleburg Heights	Ohio
United States	Premier Medical Group of the Hudson Valley	Poughkeepsie	New York
United States	Urology San Antonio	San Antonio	Texas
United States	Urology of San Bernardino	San Bernardino	California
United States	Regional Urology LLC	Shreveport	Louisiana
United States	Associated Medical Professionals	Syracuse	New York
United States	Chesapeake Urology	Towson	Maryland
United States	Urology of Virginia	Virginia Beach	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Veru Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in Serum PSA	Change in serum PSA concentration comparing baseline to day 30, baseline to day 60 and baseline to day 84 for each treatment group	84 Days
Other	Change in Serum Total Testosterone	Change in serum total testosterone concentration comparing baseline to day 30, baseline to day 60 and baseline to day 84 for each treatment group	84 Days
Other	Change in Serum Free Testosterone	Change in serum free testosterone concentration comparing baseline to day 84	84 days
Other	Change in Serum SHBG	Change in serum SHBG concentration comparing baseline to day 30, baseline to day 60 and baseline to day 84 for each treatment group	84 days
Other	Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)Sess Safety	Incidence of Treatment-Emergent Adverse Events will be tabulated by MedDRA terms and system organ class. The incidence of AEs and the maximum intensity and frequency of AEs will be summarized. The intensity of AE will be graded according to CTCAE version 4. Changes from baseline will be computed and tested for significant change from baseline to day 114	114 days
Primary	Change in Frequency of Moderate to Severe Hot Flashes at 6 Weeks	Percentage of change in frequency of moderate to severe hot flashes at 6 weeks	6 weeks
Secondary	Percentage Change in Severity of Moderate to Severe Hot Flashes at 6 Weeks	Change in severity of moderate to severe hot flashes compared to baseline at 6 weeks	6 weeks
Secondary	Change of Frequency of Moderate to Severe Hot Flashes at Week 12	Mean change in frequency of moderate to severe hot flashes compared to baseline at weeks 12	Weeks 12
Secondary	Change in Severity of Moderate to Severe Hot Flashes at Week 12	Mean change in severity of moderate to severe hot flashes compared to baseline at week 12	Week 12
Secondary	Change in Bone Turnover Markers C-telopeptide (CTX)	Change in C-telopeptide concentration at day 84 compared to baseline	84 days
Secondary	Change in Bone Turnover Markers Alkaline Phosphatase	Change in bone specific alkaline phosphatase at day 84 compared to baseline	84 days